Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrödinger, Inc. (Nasdaq: SDGR) is a computational science company focused on transforming molecular discovery for drug development and materials design. Its news flow reflects activity across software, collaborations, financial performance and a growing therapeutics portfolio, giving investors and industry observers insight into how its physics+AI platform is being applied in practice.
Recent press releases highlight progress in advancing Schrödinger’s physics+AI computational platform, including a predictive toxicology initiative, an AI-powered conversational interface in its Maestro graphical environment, and integration of Lilly’s TuneLab platform into LiveDesign, its cloud-native enterprise informatics environment. These updates illustrate how the company combines physics-based simulations with AI and machine learning to address challenges such as data scarcity in drug discovery.
Schrödinger’s news also covers collaborations and co-founded companies. Examples include expanded research agreements with Ajax Therapeutics, Lilly and Otsuka Pharmaceutical, as well as developments from Nimbus, Structure Therapeutics and Copernic Catalysts, all of which use Schrödinger’s platform in different ways. News items have described positive data for molecules such as zasocitinib, co-invented by Schrödinger and Nimbus, and the creation of a new ammonia synthesis catalyst in collaboration with Copernic.
On the corporate side, SDGR news includes quarterly financial results, updated financial guidance, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Pipeline updates for proprietary programs such as SGR-1505, SGR-3515, SGR-5573 and SGR-6016 appear alongside platform and partnership announcements, providing a combined view of software and drug discovery activities.
Investors and researchers can use the SDGR news page to follow earnings releases, platform enhancements, regulatory designations, collaborative milestones and governance disclosures that shape the company’s trajectory.
Schrödinger, Inc. (Nasdaq: SDGR) is hosting its second annual Educator's Day to discuss the integration of computational tools in education. The event, featuring live webinars from esteemed educators, aims to equip K-12 and university students with modern scientific skills. Keynote speaker Maria Gallardo-Williams highlighted the effectiveness of virtual reality labs developed during the COVID-19 pandemic, which assisted over 50 universities. Schrödinger's software platform accelerates drug and materials discovery, emphasizing hands-on learning and bridging technology gaps in education.
Schrödinger (Nasdaq: SDGR) announced its participation in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 3:30 p.m. ET. The live presentation will be accessible in the investors section of Schrödinger's website and archived for seven days. Schrödinger is renowned for its innovative physics-based software platform that accelerates the discovery of therapeutics and materials, engaging biopharmaceutical and industrial sectors worldwide.
Schrödinger, Inc. (Nasdaq: SDGR) has appointed Arun Oberoi to its Board of Directors, effective May 17, 2022. Mr. Oberoi, a former executive vice president at Red Hat, will also serve on the Audit Committee. His extensive experience in enterprise software is expected to support Schrödinger's growth and mission to enhance human health. Schrödinger specializes in a physics-based software platform that accelerates the discovery of therapeutics and materials, aiming to improve efficiency and reduce costs significantly compared to traditional methods.
Schrödinger (Nasdaq: SDGR) announced its participation in the Citi Biotech Virtual Co-Panel Day on May 18, 2022, at 10:00 a.m. ET. Karen Akinsanya, president of R&D, Therapeutics, will discuss Software, AI, and Bioinformatics in Drug Development. The panel will be accessible live via the investors section of Schrödinger’s website and will be archived for a week afterward. Schrödinger's innovative software platform significantly enhances the discovery of therapeutics and materials, supporting clients globally since its inception in 1990.
Schrödinger, Inc. (SDGR) reported a strong first quarter of 2022 with total revenue of $48.7 million, representing a 51% increase year-over-year. Software revenue reached $33.1 million, a 26% rise, driven by customer adoption. Gross profit was $28 million, a 73% increase, while the company recorded a net loss of $34.5 million. Schrödinger is on track with its pipeline, notably planning an IND submission for its MALT1 inhibitor, SGR-1505, in the first half of 2022. The company maintains its 2022 financial outlook, predicting total revenue of $161 million to $181 million.
Schrödinger (Nasdaq: SDGR) will report its Q1 2022 financial results on May 4, 2022, after market close. The company will host a conference call at 4:30 p.m. ET to discuss the results. Schrödinger uses a physics-based software platform for drug and materials discovery, leading to rapid and cost-effective development. Founded in 1990, it collaborates with global biopharmaceutical and industrial firms, academic institutions, and government labs, employing over 650 staff across 70 countries.
Schrödinger, Inc. (Nasdaq: SDGR) has granted stock options for 101,715 shares to 30 newly hired employees as an incentive for their employment acceptance. The options were issued under the company’s 2021 Inducement Equity Incentive Plan with an exercise price of $29.82, equal to the closing stock price on April 15, 2022. The vesting period is structured, with U.S. employees vesting monthly over four years, while employees in India and Japan will vest annually over three years. This move aims to enhance talent acquisition and retention as Schrödinger continues to innovate in drug discovery.
Schrödinger, Inc. (Nasdaq: SDGR) presented promising preclinical data on its Wee1 inhibitors at the AACR Annual Meeting. These inhibitors demonstrate strong anti-tumor activity and potential for monotherapy and combination therapy. The company plans to identify a Wee1 development candidate by 2022 and submit an IND application to the FDA in 2023. The study highlighted a compound, STC-8123, showing high selectivity and sustained anti-tumor effects without significant side effects, indicating a favorable dosing regimen.
Schrödinger, Inc. (Nasdaq: SDGR) announced the granting of non-statutory stock options for 42,425 shares to 17 new employees on March 15, 2022. This grant, part of the 2021 Inducement Equity Incentive Plan, serves as an inducement for employment acceptance, compliant with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at $28.81 per share, equal to the closing price on the grant date. Options vest over four years, with different vesting schedules for U.S. and India-based hires.
Schrödinger is focused on enhancing drug discovery through its physics-based software platform.
Schrödinger, Inc. (Nasdaq: SDGR) announced promising preclinical data on its small-molecule Wee1 inhibitors, to be presented at the AACR Annual Meeting in New Orleans (April 8-13, 2022). These inhibitors may induce apoptosis in tumor cells by triggering DNA damage. Early studies show significant anti-tumor activity in ovarian and uterine cancers. Schrödinger plans to select a development candidate later this year, with an emphasis on strong pharmacodynamics and potential use as monotherapy or in combination therapy.
FAQ
What is the current stock price of Schrodinger (SDGR)?
What is the market cap of Schrodinger (SDGR)?
